NorthView Acquisition Corp closes merger with Profusa, Inc., becoming Profusa, Inc.

Profusa, Inc.

Profusa valued at $155M; exchange ratio of 0.94 shares of new common stock per Profusa share.
Issued $10M principal PIPE convertible note to Ascent Partners at 10% OID, 18-month maturity.
Founder shares locked up for 8 months; other lock-up periods from 6 to 12 months.
Profusa is a clinical-stage digital health company with CE-marked Lumee Oxygen and Lumee Glucose in trials.
PIPE Investors subject to lock-up and registration rights; security interest granted on assets.

item 1.01item 2.01item 2.03item 3.02item 9.01item 3.03item 5.01item 5.02item 5.06item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.